Literature DB >> 20526893

Mast cell activation disorder masquerading as pure red cell aplasia.

Lawrence B Afrin.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20526893     DOI： 10.1007/s12185-010-0605-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  4 in total

1.  Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder.

Authors:  Gerhard J Molderings; Ulrich W Kolck; Christian Scheurlen; Michael Brüss; Jürgen Homann; Ivar Von Kügelgen
Journal:  Scand J Gastroenterol       Date:  2007-09       Impact factor: 2.423

Review 2.  The biology of Kit in disease and the application of pharmacogenetics.

Authors:  Cem Akin; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2004-07       Impact factor: 10.793

3.  Imatinib for systemic mast-cell disease.

Authors:  A Pardanani; M Elliott; T Reeder; C Y Li; E J Baxter; N C P Cross; A Tefferi
Journal:  Lancet       Date:  2003-08-16       Impact factor: 79.321

Review 4.  Acquired pure red cell aplasia: updated review of treatment.

Authors:  Kenichi Sawada; Naohito Fujishima; Makoto Hirokawa
Journal:  Br J Haematol       Date:  2008-05-28       Impact factor: 6.998
  4 in total
  2 in total

1.  Aggressive Systemic Mastocytosis in Association with Pure Red Cell Aplasia.

Authors:  Dhauna Karam; Sean Swiatkowski; Mamata Ravipati; Bharat Agrawal
Journal:  Case Rep Hematol       Date:  2018-07-08

Review 2.  Pharmacological treatment options for mast cell activation disease.

Authors:  Gerhard J Molderings; Britta Haenisch; Stefan Brettner; Jürgen Homann; Markus Menzen; Franz Ludwig Dumoulin; Jens Panse; Joseph Butterfield; Lawrence B Afrin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-30       Impact factor: 3.000
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.